Can bronchial secretion cultures identify the etiologic agent of COVID-19-associated pulmonary aspergillosis in ICU patients? Comparison with a species-specific Aspergillus PCR in serum.

Aspergillus spp. isolated from non-BAL cultures of coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) patients may reflect colonization rather than infection. Sera (n = 181) from 49 adult ICU CAPA patients (24 probable and 25 possible CAPA) with bronchial secretions (BS) culture positive for Aspergillus spp. were collected and tested for Aspergillus DNA detection by species-specific real-time PCR. Overall, 30/49 (61%) patients were PCR positive. BS culture/serum PCR agreement was moderate (21/30; 70%). Based on serum PCR positive patients, all CAPAs were due to A. fumigatus (80%), A. flavus (10%), and A. terreus (10%). No A. niger/A. nidulans or mixed infections were found despite positive BS cultures.

Discordant results were observed between bronchial secretion cultures and species-specific serum PCR (30%) with A. fumigatus being by far the most common etiological agent of CAPA (80%). No A. niger/A. nidulans or mixed infections were found despite positive cultures.

Effect of different storage conditions on the fit of 3D-printed occlusal devices used to treat temporomandibular disorders.

STATEMENT OF PROBLEM: Research-based storage guidelines for 3-dimensional (3D)-printed occlusal devices are lacking. PURPOSE: The purpose of this in vitro study was to investigate the dimensional stability of the internal surface of 3D-printed occlusal devices under different storage conditions. MATERIAL AND METHODS: Maxillary and mandibular dental casts were scanned and exported to a 3D printer to fabricate 30 occlusal devices. The specimens were stored under 3 different conditions (n=10): air dried and stored under natural light (group DL), stored in a dark container with water (group W), and air dried and stored in a dark container (group D). The intaglio surfaces of the occlusal devices were scanned by a laboratory scanner at 4 time points: immediately after polymerization (t0, control), after 1 day (t1), after 7 days (t2), and after 27 days (t3). The dimensional changes of the fitting surfaces between t0 and t1 (Δt1), t0 and t2 (Δt2), and t0 and t3 (Δt3) were measured by using best fit alignment in a surface analysis software program. In addition, comparisons were made between the posterior and anterior sections. Statistical analysis was completed with Kolmogorov-Smirnov, 1-way ANOVA, Friedman, Kruskal-Wallis, Mann-Whitney, and unpaired t tests. RESULTS: The root mean square (RMS) of group DL between Δt1 and Δt2 (P=.002) and between Δt1 and Δt3 (P=.002) showed a statistically significant difference. The RMS of group W between Δt1 and Δt3 (P=.008) showed a statistically significant difference. When the groups were compared with each other at the different time points, the DL group showed a statistically significant difference compared with groups W and D at Δt1. The examination of different areas of the occlusal device (right molar, incisor, and left molar sites) indicated no statistically significant differences in RMS among all groups (P>.05). CONCLUSIONS: The occlusal devices of group DL showed the least dimensional change of the fitting surface for Δt1 in comparison with group W and D, while no statistically significant differences were found among the groups for Δt2 and Δt3. In terms of the different locations, no statistically significant differences were found among the 3 locations for any given group after 27 days.

In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates.

Metallo-beta-lactamase (MBL)-producing Gram-negative bacteria are increasing worldwide and very few agents are active against these pathogens. Taniborbactam (formerly VNRX-5133) is a newly developed bicyclic boronate beta-lactamase inhibitor that directly inhibits all four Ambler classes of beta-lactamases. In the present study the in vitro activity of cefepime or meropenem combined with taniborbactam against 100 Klebsiella pneumoniae and cefepime combined with taniborbactam against 100 Pseudomonas aeruginosa molecularly characterized MBL-producing strains were investigated using ISO standard broth microdilution assays and compared with a panel of antimicrobial agents that are used in clinical practice (amikacin, aztreonam, ciprofloxacin, levofloxacin, gentamicin, piperacillin/tazobactam, imipenem, tigecycline, ceftolozane-tazobactam, cefepime-tazobactam, meropenem-vaborbactam, ceftazidime-avibactam). For K. pneumoniae isolates, the MIC90 values were ≥64 mg/L for all drugs except cefepime-taniborbactam (16 mg/L; 87% inhibited at ≤8/4 mg/L), meropenem-taniborbactam (4 mg/L; 94% inhibited at ≤8/4 mg/L) and tigecycline (8 mg/L), with high levels of resistance (≥65%) found for all approved comparator antimicrobials tested. For P. aeruginosa, the MIC90 values were ≥64 mg/L for all drugs except aztreonam (32 mg/L), cefepime-taniborbactam (32 mg/L; 88% inhibited at ≤16/4 mg/L) and ciprofloxacin (32 mg/L), with high levels of resistance (≥73%) for all approved drugs except aztreonam (27%). Taniborbactam reduced cefepime and meropenem MICs by a median 5 and 7 two-fold dilutions to ≤8 mg/L in 87% and 94% of MBL-producing K. pneumoniae isolates, and cefepime MICs by a median 5 two-fold dilutions to ≤16 mg/L in 86% of MBL-producing P. aeruginosa, respectively. The combinations cefepime-taniborbactam and meropenem-taniborbactam are promising alternative treatment options for infections by MBL-producing isolates.

Candida vaginitis: virulence, host response and vaccine prospects.

Vulvovaginal candidiasis is a common mucosal infection affecting a large proportion of women with some of them affected by recurrent often intractable forms of the disease. Thus, there is an increasing interest in understanding the pathogenesis of this disease. The aim of our work was to characterize, in animal models of vaginal candidiasis, the components of the host-fungus interaction at the mucosal level.The evidence of an immune response in the vaginal compartment was very encouraging to identify the proper targets for new strategies for vaccination or immunotherapy of vaginal candidiasis. Aspartyl-proteinase (Sap2), which is an important immunodominant antigens and virulence factors of C.albicans acting in mucosal infections, was assembled with virosomes and a vaccine PEV7 was obtained. The results obtained in the mouse model and in the clinical trial conducted by Pevion on women have evidenced that the vaccine PEV7, intravaginally administered, has an encouraging therapeutic potential for the treatment of recurrent vulvovaginal candidiasis. This opens the way to a modality for anti-Candida protection at mucosal level.

Prevalence of Ureaplasma urealyticum and Mycoplasma hominis in women with chronic urinary symptoms.

OBJECTIVES: To assess the prevalence of Ureaplasma urealyticum and Mycoplasma hominis in women experiencing chronic urinary symptoms. METHODS: Urine, vaginal, and urethral samples obtained from 153 women presenting with chronic voiding symptoms were tested for the presence of pathogens including U. urealyticum and M. hominis. Patients with positive cultures for Mycoplasma were treated with a single dose of 1 g azithromycin and followed up 1 month after therapy. Patients with persistent infection received 100 mg doxycycline orally, twice daily for 7 days, according to the results of the susceptibility test. The patients were asked to rate the severity of their symptoms at their initial visit and after treatment. RESULTS: U. urealyticum was detected from > or =1 site in 81 women (52.9%), and M. hominis was detected in 5 patients (3.3%), always in association with U. urealyticum. At follow-up, 77 patients (95.1%) initially positive for Mycoplasma had negative cultures; the cultures of 4 (4.9%) remained positive for U. urealyticum and became negative after the second therapeutic regimen. A significant improvement in all symptoms was observed in women with positive cultures for Mycoplasma after therapy. CONCLUSIONS: A high prevalence of U. urealyticum was observed in women with unexplained chronic voiding symptoms. Testing for the presence of U. urealyticum and M. hominis in the urogenital tract could prove valuable for the management of a significant percentage of chronic urinary symptoms in women through appropriate treatment.

Fenticonazole activity measured by the methods of the European Committee on Antimicrobial Susceptibility Testing and CLSI against 260 Candida vulvovaginitis isolates from two European regions and annotations on the prevalent genotypes.

The activity of fenticonazole was studied against 260 West and Southeast European vulvovaginal candidiasis isolates, and low MICs were displayed. Fenticonazole was assessed by European Committee on Antimicrobial Susceptibility Testing and CLSI microdilution methods for the first time, and the results showed excellent agreement (97%) and significant interclass correlation coefficient (P < 0.0001). Also, the levels of agreement for the results for itraconazole, fluconazole, and ketoconazole were 84%, 90%, and 98% (P < 0.0001), respectively. Multilocus typing by PCR fingerprinting and subsequent cluster analysis delineated geographically associated alignments for Candida albicans and fluconazole resistance-related clusters for Candida glabrata.